Revolution Medicines (RVMD) Capital Expenditures (2019 - 2026)

Revolution Medicines has reported Capital Expenditures for 8 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 69.32% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $9.1 million, a 41.14% decrease from a year earlier, with the FY2025 full-year figure at $16.0 million, up 55.12% from the prior year.
• Capital Expenditures was $2.3 million for Q2 2026 at Revolution Medicines, up from $1.5 million in the prior quarter.
• The five-year high for Capital Expenditures was $7.4 million in Q2 2025, with the low at -$766000.0 in Q4 2023.
• Average Capital Expenditures over 5 years is $2.7 million, with a median of $2.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 676.43% in 2022, then sank 126.63% in 2023.
• Over 5 years, Capital Expenditures stood at $2.9 million in 2022, then tumbled by 126.63% to -$766000.0 in 2023, then jumped by 259.53% to $1.2 million in 2024, then soared by 57.53% to $1.9 million in 2025, then increased by 18.75% to $2.3 million in 2026.
• The last three Capital Expenditures figures came in at $2.3 million (Q2 2026), $1.5 million (Q1 2026), and $1.9 million (Q4 2025), per Business Quant data.